Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2014

Intangible Assets

Schedule of intangible assets

	June 30, 2014
(In thousands)	Weighted Average Remaining Amortization Period (Years)	Gross Carrying Value		Accumulated Amortization			Net Carrying Value
FDA approval and launch of BREO® ELLIPTA® in the U.S.	15.2	$	60,000	$	(2,526	)	$	57,474
MHLW approval and launch of RELVAR® ELLIPTA® in Japan	14.4	20,000		(778		)	19,222
European Commission approval and launch of RELVAR® ELLIPTA®	14.5	30,000		(1,000		)	29,000
FDA approval and launch of ANORO® ELLIPTA® in the U.S.	15.2	60,000		(652		)	59,348
European Commission approval and launch of ANORO® ELLIPTA®	15.2	30,000		(164		)	29,836
Total intangible assets		$	200,000	$	(5,120	)	$	194,880

	December 31, 2013
(In thousands)	Weighted Average Remaining Amortization Period (Years)	Gross Carrying Value		Accumulated Amortization			Net Carrying Value
FDA approval and launch of BREO® ELLIPTA® in the U.S.	15.7	$	60,000	$	(632	)	$	59,368
MHLW approval and launch of RELVAR® ELLIPTA® in Japan	14.9	20,000		(111		)	19,889
European Commission approval of RELVAR® ELLIPTA®	15	15,000		—			15,000
FDA approval of ANORO® ELLIPTA® in the U.S.	15.3	30,000		—			30,000
Total intangible assets		$	125,000	$	(743	)	$	124,257